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1588–95.Hypercholesterolemia
Abolishes High-Density
Lipoprotein–Related
Cardioprotective Effects
in the Setting of
Myocardial InfarctionEpidemiological studies have consistently reported
that high-density lipoprotein (HDL) cholesterol levels
are inversely associated with the risk of cardiovascular
disease (CVD) (1). In fact, plasma-derived and syn-
thetic HDL, and/or its derivatives, have been shown
to exert various cardiovascular protective effects
ranging from reverse cholesterol transport, athero-
sclerotic plaque stabilization, improvement of endo-
thelial dysfunction (2), and most lately, limiting
infarct size (3). However, in this latter regard, it
remains unknown whether the presence of cardio-
vascular risk factors attenuates HDL-related cardio-
vascular protection. We investigated whether the
presence of high low-density lipoprotein cholesterol
levels, a prominent risk factor for CVD, affects ability
of HDL to exert direct cardioprotective effects. We
conducted this study in a pre-clinical animal model of
myocardial infarction (MI) as a biological readout of
the differential effects of HDL when formed in a high-
cholesterol pathological environment.
Young healthy pigs were distributed to receive
during 10 days either a regular normocholesterolemic
chow (NC) or a high-cholesterol diet (HyC) (non-HDL
cholesterol 38.2  3.5 mg/dl vs. 218.6  27.6 mg/dl,
respectively; p < 0.0001). On day 10, HDLs were iso-
lated from NC- and HyC-fed animals by sequential
ultracentrifugation (NCHDL and HyCHDL, respectively)
and were quantiﬁed, sterilized, lyophilized, and kept
at 80C until use. Another set of young healthy pigs
were randomized to receive 2 intravenous infusions
3 days apart of NCHDL (15 mg/kg; n ¼ 6), HyCHDL
(15 mg/kg; n ¼ 6), or vehicle (phosphate-buffered sa-
line; n ¼ 6). One day after the second infusion, ani-
mals were subjected to 60-min closed-chest coronary
balloon occlusion followed by reperfusion (experi-
mental MI). Echocardiography revealed that 60 min
of ischemia signiﬁcantly and similarly worsened left
ventricle ejection fraction in all animals showing
the homogeneity of the employed methodologicalapproach (vehicle: 19.6  4.8%; NCHDL: 20.6  3.2%;
HyCHDL: 17.3  2.1%; p < 0.05 vs. prior MI induction).
Three days post-MI, all animals underwent cardiac
magnetic resonance, and the following sequences
were acquired: 1) “cine” (balanced steady-state free
precession) imaging sequence to assess wall motion
and cardiac function; 2) T2-short tau inversion re-
covery sequence to assess myocardial edema; 3) T2* to
evaluate intramyocardial hemorrhage; 4) early gado-
linium enhancement to evaluate the degree of no-
reﬂow; and 5) late gadolinium enhancement to assess
the extent of myocardial necrosis. Data were normally
distributed (Shapiro-Wilk Test) and analysis of vari-
ance, Fisher least signiﬁcant difference, and post-hoc
Student-Newman-Keuls analyses were performed.
A value of p < 0.05 was considered signiﬁcant.
Infusion of NCHDL before MI resulted in a signiﬁ-
cantly smaller infarct size, in terms of both absolute
infarct mass and percentage of the left ventricle,
compared with vehicle-infused animals (Table 1). This
protective effect did not occur in animals infused
with HyCHDL. T2-weighted sequences revealed no
differences in the extent of area-at-risk among
the 3 groups. Consequently, the extent of salvage
myocardium was signiﬁcantly larger in the NCHDL-
administered group compared with the HyCHDL and
vehicle control groups. The extent of no-reﬂow was
also signiﬁcantly attenuated in the NCHDL-infused
group compared with HyCHDL and vehicle animals
and directly correlated with the extent of necrosis
(p < 0.05; R ¼ 0.63). No differences were observed
between HyCHDL-recipient animals and vehicle con-
trols with regard to infarct size, myocardial salvage,
and no-reﬂow. The extent of hemorrhage was compa-
rable among the 3 groups. Although left ventricular
ejection fraction assessed 3 days post-MI did not differ
between the groups (Table 1), left ventricular volumes
signiﬁcantly improved in NCHDL-recipient animals
compared with HyCHDL- and vehicle-infused animals.
We describe, for the ﬁrst time, that hypercholes-
terolemia, a common risk factor for CVD, impairs the
cardioprotective properties commonly associated
with HDL. We provide evidence that HDL particles
formed in a high low-density lipoprotein cholesterol
niche lose their capability to attenuate myocardial
damage in the setting of MI. As such, the degree of
cardiac injury and cardiac impairment observed in
HyCHDL-infused animals is comparable to that
observed in vehicle-infused animals. These observa-
tions suggest that the presence of comorbidities may
alter HDL’s beneﬁcial properties. Particularly note-
worthy, in contrast to primary prevention, the asso-
ciation between HDL cholesterol and cardiovascular
events is altered in patients with established CVD
TABLE 1 3-T CMR Data
3-T CMR (Day 3 Post-MI) Vehicle NCHDL HyCHDL
Functional parameters
LV ejection fraction 43.7  2.2 48.0  2.7 43.4  1.4
LV end-diastolic
volume
100.1  5.5 85.4  1.2* 104.8  3.6
LV end-systolic
volume
56.8  4.6 44.3  2.3* 59.1  1.3
Stroke volume 43.3  1.9 41.0  2.4 45.7  2.9
Anatomic parameters
Area-at-risk, g LV 21.3  1.4 18.1  1.2 20.1  1.1
LV mass, g 73.2  2.9 74.7  2.7 81.6  6.3
Infarct size, % LV 23.3  1.8 13.8  1.3* 19.2  1.0
Infarct mass, g LV 17.4  1.2 10.3  1.1* 15.4  0.7
Myocardial salvage 3.9  0.5 7.8  0.9* 4.7  1.0
Myocardial salvage
index
0.18  0.02 0.43  0.04* 0.23  0.04
Hemorrhage, g LV 2.0  0.3 2.0  0.4 2.4  0.4
No-reﬂow, g LV 2.5  0.2 1.9  0.1* 3.1  0.4
Values are mean  SEM. *p < 0.05 vs. vehicle and animals infused with high-
density lipoprotein isolated from hypercholesterolemic-fed pigs (HyCHDL).
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricle/ventricular;
MI ¼myocardial infarction; NCHDL ¼ animals infused high-density lipoprotein from
normocholesterolemic-fed pigs.
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2470(4), and HDL-raising therapies in CVD patients
have yielded disappointing results (5). Further
studies are warranted to fully characterize HDL
functionality and structural remodeling in different
clinical conditions.*Gemma Vilahur, PhD
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2089–99.Understanding the
Mechanism of T-Wave
Inversion in Athletes
May Be Key to Best
ManagementWe read with great interest the recent paper by
Zaidi et al. (1) demonstrating that T-wave inversion
(TWI) in the precordial leads is a nonspeciﬁc ﬁnding
in asymptomatic athletes and that other parameters
have to be evaluated before diagnosing arrhythmo-
genic right ventricular cardiomyopathy (ARVC). This
is not so surprising given the century-old observa-
tions of Swedish physician Henschen that the car-
diac apex is laterally displaced in athletes, thereby
also inferring displacement of the right ventricle
relative to standardized electrocardiography lead
positions. Using magnetic resonance imaging, we
recently validated this observation by demonstrating
that TWI in leads V1 through V4 was determined by
the position rather than morphology of the right
ventricle (2). Thus, we agree that TWI can be
explained by factors other than right ventricular
(RV) pathology in a majority of asymptomatic
athletes.
However, precordial TWI should raise the suspi-
cion of ARVC, especially in endurance athletes
such as cyclists and triathletes. We coined the term
“exercise-induced ARVC” after observing that a
majority of athletes presenting for investigation of
arrhythmias met task force criteria for ARVC
despite the fact that evidence of an inherited syn-
drome was absent in the vast majority (3,4). Pre-
cordial TWI was present in 39% to 71% of those
athletes, and, hence, is an important ﬁrst-line
